Eastwood Bio-Medical Canada (EBM) AI Stock Analysis

5 Followers

Eastwood Bio-Medical Canada

(TSXV:EBM)

Select Model

Rating:56Neutral

Price Target:CAD 2.00▲(14.29% Upside)

Action:reiterated

Date:10/01/26

TSE:EBM carries a low overall score primarily driven by severe fundamental weaknesses, including deep negative equity, ongoing cash burn, and a highly unfavorable negative valuation. However, the stock's poor fundamental profile is currently being temporarily offset by exceptionally strong technical momentum, with the price in a robust uptrend across all major moving averages. Investors should exercise extreme caution, as the underlying structural and solvency risks heavily outweigh the short-term positive price action.

Positive Factors

Revenue reboundThe sharp TTM revenue rebound indicates renewed demand for the company’s products or services and provides a stronger base for operating leverage. If the improvement persists, greater scale could support reinvestment, customer development, and eventual progress toward sustainable profitability.

Negative Factors

Deeply negative equityDeeply negative and worsening equity reflects accumulated losses and leaves the company with a weak capital base. This limits financial flexibility, increases dependence on external funding, and raises solvency and refinancing concerns even though reported debt is modest in absolute dollars.

Eastwood Bio-Medical Canada (EBM) vs. iShares MSCI Canada ETF (EWC)

Market Cap: CAD 120.55M
Dividend Yield: ―
Average Volume (3M): 7,744
Price to Earnings (P/E): -564.5
Beta (1Y): 0.59
Revenue Growth: 36.59%
EPS Growth: 43.33%
Country: Canada
Employees: 3
Sector: General
Sector Strength: 55
Industry: Medical - Pharmaceuticals

Eastwood Bio-Medical Canada Business Overview & Revenue Model

Company Description

Eastwood Bio-Medical Canada Inc., established in Richmond, Canada, in 2010, is a company focused on the worldwide marketing and distribution of natural health products. Operating under the Eleotin brand, their offerings are available across Canada, t...

Eastwood Bio-Medical Canada Financial Statement Overview

Summary

Financial health is severely distressed, characterized by worsening negative equity, ongoing cash burn, and consistent unprofitability. While net losses have narrowed slightly, the lack of positive free cash flow poses significant solvency risks.

Income Statement

35Negative

Balance Sheet

15Very Negative

Cash Flow

25Negative

Financial statement breakdown
Breakdown	TTM	Jan 2026	Jan 2025	Oct 2023	Oct 2022	Jan 2022
Income Statement
Total Revenue	812.12K	782.08K	702.08K	867.94K	1.30M	981.05K
Gross Profit	538.18K	506.03K	454.39K	440.51K	902.74K	458.37K
EBITDA	-238.60K	-309.73K	-342.05K	-410.58K	-32.33K	-495.50K
Net Income	-231.56K	-332.77K	-455.87K	-546.60K	-160.58K	-611.34K
Balance Sheet
Total Assets	256.96K	218.77K	274.29K	489.14K	584.53K	691.12K
Cash, Cash Equivalents and Short-Term Investments	3,528	17.70K	0	18.45K	39.84K	20.87K
Total Debt	63.65K	78.01K	79.61K	23.08K	62.25K	31.35K
Total Liabilities	2.04M	1.85M	1.57M	1.33M	878.73K	835.44K
Stockholders Equity	-1.78M	-1.63M	-1.30M	-840.80K	-294.20K	-144.32K
Cash Flow
Free Cash Flow	-9,420	19.30K	-15.22K	-16.89K	-7,299	-121.79K
Operating Cash Flow	-9,428	19.30K	-15.22K	-16.89K	-4,294	-116.21K
Investing Cash Flow	0	0	0	0	-3,005	-5,574
Financing Cash Flow	-7,688	-211	-4,619	-4,503	26.27K	20.00K

Eastwood Bio-Medical Canada Technical Analysis

Technical Analysis SentimentNeutral

Last Price1.75

Price Trends

50DMA1.85Negative

100DMA1.56Positive

200DMA1.16Positive

Market Momentum

MACD-0.03Positive

RSI45.26Neutral

STOCH39.58Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:EBM, the sentiment is Neutral. The current price of 1.75 is below the 20-day moving average (MA) of 1.84, below the 50-day MA of 1.85, and above the 200-day MA of 1.16, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 45.26 is Neutral, neither overbought nor oversold. The STOCH value of 39.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:EBM.

Eastwood Bio-Medical Canada Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TSE:EBM against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSE:EBM	56Neutral	CAD 120.55M	-564.52	13.66%	―	36.59%	43.33%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TSE:ARCH	43Neutral	CAD 63.18M	-21.88	74.79%	―	―	-15.53%
TSE:ATLE	42Neutral	CAD 44.29M	-0.76	-2099.75%	―	-96.13%	88.13%
TSE:ADK	41Neutral	CAD 39.74M	-7.99	9999.00%	―	-36.92%	13.03%
TSE:SONA	37Underperform	CAD 33.16M	-12.62	448.05%	―	―	24.65%

* General Sector Average

Performance Comparison

TSE:EBM and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TSE:EBM	Eastwood Bio-Medical Canada	1.75	1.00	133.33%
TSE:ARCH	Arch Biopartners	0.93	-0.09	-8.82%
TSE:ADK	Diagnos Inc	0.33	0.05	17.86%
TSE:ATLE	Willow Biosciences	0.10	-0.08	-44.12%
TSE:ZYUS	Zyus Life Sciences Corporation	0.40	-0.29	-42.03%
TSE:SONA	Sona Nanotech, Inc	0.27	-0.24	-47.06%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 01, 2026

Eastwood Bio-Medical Canada AI Stock Analysis